The most covered medications by health insurance in France

In France, the pharmaceutical landscape managed by Health Insurance reflects a constantly evolving health reality, where certain medications dominate due to their frequency of use and financial importance. Data from 2024-2025 confirms that the consumption of products such as paracetamol, respiratory treatments, and anti-inflammatories remains at the heart of public health priorities. These medications, often generic, benefit from broad coverage, thus facilitating access to effective treatment. Furthermore, major players in the pharmaceutical industry such as Sanofi, Servier, Pfizer, and Roche play a key role in supplying these products, highlighting a system where innovation, regulation, and social coverage seek to reconcile in a context of cost control.

The snapshot of the most reimbursed and prescribed medications also highlights a major economic challenge, namely controlling healthcare expenses in the face of sometimes excessive or inappropriate consumption. It is within this framework that health authorities and Health Insurance regularly publish detailed reports. This transparency helps identify trends, implement corrective measures when necessary, and understand the real needs of the population. The 2024 ranking notably demonstrates how common molecules, sometimes intended for trivial conditions, can heavily impact the social security budget while already being essential daily care.

Faced with this fragile balance, future issues concern both the quality of treatments, the emergence of new pathologies to treat, and the management of the risk of cost overruns. This detailed analysis sheds light on stakeholders, treatments, and key figures that currently structure medication reimbursement in France.

Most reimbursed medications: an overview of the top 10 in France

The ranking of medications most supported by Health Insurance reveals a marked concentration on a few essential molecules for public health. Leading the list, unsurprisingly, are paracetamol-based treatments such as Doliprane and Dafalgan, which form the cornerstone of symptomatic treatment for pain and fever. Their popularity is explained by their efficacy, generally good tolerance, and widespread prescription, especially in guided self-medication.

The list of reimbursed medications also prominently features chronic treatments and drugs for respiratory, digestive, or cardiovascular conditions, emphasizing the overall nature of French medical needs. Labs such as Sanofi, GSK (GlaxoSmithKline), and AstraZeneca are particularly involved in producing these products, benefiting from a market where therapeutic optimization is also a political objective.

• 💊 Paracetamol (Doliprane, Dafalgan)
• 💊 Bronchodilators (Ventoline)
• 💊 Antispasmodics (Spasfon)
• 💊 Statins (cholesterol-lowering drugs)
• 💊 Antihypertensives
• 💊 Non-steroidal anti-inflammatory drugs (NSAIDs)
• 💊 Oral antidiabetics
• 💊 Antiallergics (inhaled corticosteroids)
• 💊 Psychotropic drugs
• 💊 Antibiotics

Name of medication 🏥	Therapeutic class ⚕️	Manufacturing laboratory 🏢	Part covered by Health Insurance (%) 💰	Number of boxes sold in 2024 📦
Doliprane (paracetamol)	Painkillers	Sanofi	65%	45 million
Ventoline (salbutamol)	Bronchodilators	GSK	65%	13 million
Spasfon (phloroglucinol)	Antispasmodics	Servier	65%	9 million
Atorvastatin	Hypolipidemics	Pfizer	65%	8 million
Ramipril	Antihypertensives	Bayer	65%	7 million
Ibuprofen	NSAIDs	Roche	30%	15 million

It should be noted that coverage is based on strict criteria, also adapted according to medical prescription and therapeutic context. For example, some medications, although widely prescribed, see their reimbursement rate limited to 30%, like ibuprofen, which remains a staple in symptomatic inflammatory treatment.

Impact of medication coverage on the budget of Health Insurance

The financial management of medication expenses is a crucial issue for French Health Insurance. In 2024, the share of medications in total health expenditure accounts for a significant sum, amplified by the high consumption of certain very frequently prescribed treatments. The risk of exceeding budgeted expenditures requires constant consolidation of reimbursement conditions and increased vigilance.

According to published figures, the twenty most reimbursed medications account for nearly 28% of total pharmacy expenses, about 7.3 billion euros out of a total of 25.7 billion. This concentration illustrates the economic weight of these products within the French healthcare system and justifies efforts by pharmaceutical companies and public authorities to negotiate prices, promote substitution with generics, and ensure rational use.

• 📊 Regular expense monitoring and transparency
• 🛡️ Promotion of rational prescription
• ⚖️ Budgetary correction measures in case of drift
• 💡 Encouragement to use generics and biosimilars
• 🏛️ Involvement of laboratories (Sanofi, Bristol-Myers Squibb) in price negotiations

Year 📅	Total medication expenses 💶	Expenses of the 20 most reimbursed medications 💊	Part (%) of the key 20 medications in total expenses
2023	25.1 billion euros	7 billion euros	27.9%
2024	25.7 billion euros	7.3 billion euros	28.3%
Forecast 2025	26.3 billion euros	7.6 billion euros	28.9%

In this context, the role of pharmaceutical groups is twofold: they provide innovative treatments while being subject to price negotiations. Among them, establishments like Novartis, Merck, and AstraZeneca are particularly active in researching specialized drugs that tend to increase costs despite the need to control expenses.

The role of pharmaceutical laboratories in medication management

The pharmaceutical industry in France is dominated by a few major players who shape the therapeutic offerings supported by Health Insurance. Sanofi and Servier, two historical pillars, remain references in the production of essential medicines, especially in managing chronic and acute diseases. Additionally, multinationals such as Bristol-Myers Squibb, Pfizer, and Roche play a central role in therapeutic innovation and cutting-edge treatments.

The relationship between laboratories and Health Insurance is characterized by regular negotiations on prices, influenced by the balance between innovation, mass prescription, and cost control policies. This dynamic is essential to incorporate pharmaceutical advances while ensuring the economic viability of the system.

• 💼 Sanofi : leader in paracetamol and vaccines
• 🎯 Servier : expert in cardiology and anti-inflammatory treatments
• 💊 Bristol-Myers Squibb : innovation in immuno-oncology
• 🎓 Pfizer : major provider of cardiovascular and antiviral treatments
• 🌍 Roche : pioneer in oncology and biotechnology

Laboratory 💊	Main specialty 🏥	Market share in France (%) 📊	Notable contributions 💡
Sanofi	Painkillers, vaccines	18%	Doliprane, flu vaccines
Servier	Cardiology, antispasmodics	12%	Spasfon, medications for hypertension
Bristol-Myers Squibb	Oncology, immunology	10%	Innovative anticancer treatments
Pfizer	Cardiology, antivirals	15%	Atorvastatin, antiretroviral treatments
Roche	Oncology, biotechnology	14%	Biological oncology treatments

It should be noted that this distribution remains fragile. The arrival of new molecules, withdrawal or limitation of certain products, and evolving medical practices regularly change the landscape, requiring the Health Insurance to be increasingly flexible in management.

Generic and biosimilar medications: essential leverage for cost control

With an increasing share in medication consumption, generics are an essential lever for reducing costs for Health Insurance. These medicines, equivalent to original brand-name drugs but sold at lower costs, enable broader access to treatments without compromising quality. Laboratories such as Novartis, Bayer, and GSK (GlaxoSmithKline) offer a wide range in this area.

Furthermore, biosimilars, which replace reference biological medicines, offer significant economic potential, especially in costly therapeutic areas like oncology or rheumatology. Their development is encouraged by public authorities through measures promoting prescription and dispensing.

• 💡 Generics: average cost 30 to 70% lower than original drugs
• ♻️ Biosimilars: biologic alternatives at reduced cost
• 🏥 Easier access thanks to better coverage
• 📈 Progressive increase in their share in prescriptions
• 📉 Direct impact on reducing expenses

Type of medication 🧪	Notable examples 💊	Main laboratories 🤝	Impact on costs (%) 💰
Generics	Paracetamol, Generic Ibuprofen	Novartis, Bayer, GSK	-40% to -70%
Biosimilars	Biosimilar trastuzumab	Pfizer, Roche	-20% to -40%

However, obstacles remain, notably related to medical habits, laboratory communication policies, and public information. Determined actions aimed at strengthening confidence in these medications are already underway to ensure an economic shift benefiting the entire French healthcare system.

Chronic treatments: a heavy weight in medication management

Among all reimbursed prescriptions by Health Insurance, treatments for chronic diseases represent a significant share, due to their frequency and duration of use. Cardiovascular diseases, diabetes, chronic respiratory conditions, and mental disorders constitute the most affected segments.

The stability or even increase of these conditions in the French population contributes to maintaining a high level of medication consumption, sometimes exceeding budgetary control capacities. Regular monitoring of prescriptions is therefore a major challenge, combining control of proper use and therapeutic guidance.

• ❤️ Cardiovascular diseases: antihypertensives, statins
• 🩸 Diabetes: oral antidiabetics and insulins
• 🌬️ Chronic respiratory diseases: bronchodilators, inhaled corticosteroids
• 🧠 Mental health disorders: antidepressants, anxiolytics
• ⚖️ Monitoring and adjusting treatments to limit overconsumption

Chronic disease 🏥	Main medication class 💊	Annual prescription volume 📈	Evolution over 5 years (%) 📊
Hypertension	Antihypertensives (Ramipril, etc.)	27 million	+5%
Diabetes	Oral antidiabetics	18 million	+8%
Asthma	Bronchodilators (Ventoline)	12 million	+3%
Depression	Antidepressants	10 million	+6%

The coverage for these treatments is often comprehensive or close to 100%, acknowledging the indispensable and prolonged nature of care. This policy supports patients in their follow-up and compliance with prescriptions to avoid sometimes costly hospital complications.

Medications for acute conditions: consumption and reimbursement

Complementary to chronic treatments, medications used for acute conditions remain essential in the therapeutic arsenal, whether for infections, sudden pains, or crises. These products, although generally prescribed for a short duration, still represent a significant share of urban consumption volumes.

The consumption of antibiotics, anti-inflammatories, or analgesics raises questions about their rational use. The reimbursement policy aims to limit waste and resistance risks, while still providing broad access to effectively treat patients.

• 🦠 Antibiotics: still highly prescribed despite awareness campaigns
• 🔥 NSAIDs: cautious management of reimbursement
• ❄️ Symptoms like fever and pain: paracetamol widely used
• 💉 Symptomatic treatments: analgesics and antispasmodics
• 🔎 Enhanced surveillance of rapidly dispensing prescriptions

Acute condition 🚑	⚕️ Class	Annual volume (in millions of boxes) 📦	Reimbursement rate (%) 💶
Amoxicillin	Antibiotics	6.5	65%
Ibuprofen	NSAIDs	15	30%
Doliprane (paracetamol)	Painkillers	45	65%
Spasfon	Antispasmodics	9	65%

The main challenge remains balancing necessary use and the risks of excessive or inappropriate consumption. Health authorities, in collaboration with pharmaceutical companies like Bayer or GSK, are working to implement training and information campaigns for healthcare professionals and the general public.

Regulations and criteria for medication coverage by Health Insurance

Medication coverage by Health Insurance is based on precise and evolving regulations, defined according to several key criteria: transparency of therapeutic benefits, cost-effectiveness ratio, and medical necessity. Any new molecule or presentation must go through a rigorous assessment before being included in reimbursement.

This evaluation is primarily carried out by the Haute Autorité de Santé (HAS), which determines the reimbursement rate based on the service medical rendered (SMR) and the level of improvement of service medical rendered (ASMR). Adjustments are regularly made to accommodate pharmaceutical innovations and budget constraints.

• 📋 Evaluation by HAS based on SMR and ASMR
• 💰 Reimbursement rate varies from 15% to 100%
• 🔄 Periodic revision of reimbursements according to clinical data evolution
• 🚦 Promote medicines with high medical service rendered
• 🧾 Transparency and priority for essential medicines

Evaluation criteria 📊	Definition	Impact on management 🏥
Service Medical Rendered (SMR)	Therapeutic importance of a medicine	Determines reimbursement rate
Improvement of Service Medical Rendered (ASMR)	Comparison with existing medicines	Influences price and reimbursement negotiations
Medicine price	Set after negotiation with CEPS	Direct budget impact

The medium-term goal remains rigorous budget control while ensuring equitable access to treatments. Budget correction measures have already been launched to regulate price setting and expand the prescription of generics.

Therapeutic innovation and its integration into reimbursement

The regular emergence of innovative, sometimes revolutionary, medications generates major interest for reimbursement by Health Insurance. However, these high-cost treatments, often derived from advanced biotechnologies, pose a significant financial challenge. The French system thus needs to reconcile the promotion of innovation with strict expense control.

Groups such as Novartis, Merck, AstraZeneca, and Roche are at the forefront of this dynamic, with advances in oncology, rare diseases, and gene therapies. In close collaboration with health agencies, Health Insurance is establishing experiments and protocols to integrate these innovations into an effective public health perspective.

• 🚀 Strong support for therapeutic innovation
• 💸 High costs requiring specific negotiations
• 🧪 Pilot projects and conditional reimbursement
• 👥 Collaboration between laboratories and health authorities
• 🔍 Ongoing analysis of benefits and cost-benefit impacts

Innovative medication 🚀	Main indication	Company 🎯	Average annual cost per patient (€) 💶
Targeted oncological treatments	Breast, lung cancer	Roche, Novartis	30,000 – 50,000
Gene therapy	Rare diseases	Sanofi, Novartis	300,000 – 500,000
Immunotherapy	Some cancers	Bristol-Myers Squibb	40,000 – 60,000

The activity of research and development results in a constant evolution of the list of reimbursed medications, requiring careful monitoring to ensure a balance between accessible medical progress and responsible management of public finances.

FAQ about the most supported medications by Health Insurance in France

• ❓ Which medications are reimbursed at 100%?
  Coverage at 100% mainly concerns vital medications or those associated with long-term conditions (ALDs), such as treatments for diabetes or certain cancers.
• ❓ How is the reimbursement rate of a medication determined?
  The rate depends on the service medical rendered (SMR) and the level of improvement (ASMR) assessed by HAS, as well as budgetary considerations and negotiations with laboratories.
• ❓ Why do some highly prescribed medications have low reimbursement rates?
  This can reflect a moderate or low service medical rendered, or a policy of cost control aiming to limit misuse, as is the case for some anti-inflammatories.
• ❓ Who are the main pharmaceutical laboratories in France?
  Major leaders include Sanofi, Servier, Pfizer, Roche, Novartis, and Bayer, involved in most reimbursed treatments.
• ❓ Are generic medications as effective as brand-name originals?
  Yes, generics contain the same active substance and must meet the same quality and efficacy criteria as original medicines.

For further information, readers are invited to consult supplementary sources such as data published on Ameli Open Medic, or detailed analyses accessible via Les Furets and Le Monde.

The issues in this sector concern patients, healthcare professionals, and all economic and institutional actors, highlighting the complexity of the French pharmaceutical system and the need for ongoing adaptation to present and future challenges.

Source: www.lesfurets.com